Is This Under-the-Radar Stock a Better Coronavirus Play Than Moderna?
You don't have to be an infectious disease expert to know that Moderna (NASDAQ: MRNA) ranks among the leaders in developing a novel coronavirus vaccine. Moderna's mRNA-1273 vaccine was on the shortlist of COVID-19 vaccine candidates to receive federal funding as part of Operation Warp Speed. World Health Organization chief scientist Soumya Swaminathan thinks Moderna is in a close second place behind AstraZeneca in the race to develop a COVID-19 vaccine.
But while many people have heard of Moderna, there's a less well-known company that's also in the thick of efforts to fight COVID-19 -- Catalent (NYSE: CTLT). Is this under-the-radar stock a better coronavirus play than Moderna?
Image source: Getty Images.
Source Fool.com
